lipiodol

Phase 3Small molecule

NNanjing Chia-tai Tianqing Pharmaceutical

lipiodol is one of 59 small molecule programs targeting Surgery. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SurgeryCompleted

Hepatocellular CarcinomaUnknown status

SurgeryPreclinical

Completed

Hepatocellular CarcinomaPhase 3

Unknown status

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

lipiodol

NNanjing Chia-tai Tianqing Pharmaceutical

Phase 3

8 2

Ibrance

Pfizer

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Hepsera

Doptelet

1 6

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 7

Vermox

WWim Janssens

Preclinical

1 8

Valemetostat

Bristol-Myers Squibb

Preclinical

1 9

Alcohol

Astellas

Preclinical

—10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Not yet recruiting

Hepatocellular Carcinoma

NCT05842174

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma8 trials

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Unknown status·SSecond Military Medical University·Phase 1/2·NCT02638857·60 enrolled

Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

Unknown status·GGuangdong Provincial People's Hospital·Phase 2/3·NCT01861912·258 enrolled

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Not yet recruiting·VVA Office of Research and Development·Phase 1/2·NCT05842174·93 enrolled

Show 5 more trials

Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT02755311·198 enrolled

Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma

Withdrawn·GGuangxi Medical University·Phase 2/3·NCT02585479

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Completed·RRehab Werida··NCT05291338·107 enrolled

Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

Unknown status·FFudan University·Phase 4·NCT02631499·256 enrolled

Phase I/II Randomized, Double-Blind, First-in-Human Study of T-ACE Oil by Trans-Catheter Arterial Embolization or ChemoEmbolization (TAE/TACE) in Patients With Hepatocellular Carcinoma

Terminated·TT-ACE Medical Co., Ltd·Preclinical·NCT05435014·2 enrolled

Liver Cancer2 trials

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

Terminated·SStanford University·Phase 3·NCT02762266·13 enrolled

Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

Completed·YYale University·Phase 2·NCT01877187·39 enrolled

Colorectal Cancer1 trial

Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

Unknown status·NNanjing Chia-tai Tianqing Pharmaceutical·Phase 4·NCT01959061·320 enrolled

Effectiveness1 trial

Effectiveness of Drug Eluting TACE in Primary HCC

Unknown status·—·Phase 1·NCT04048317·75 enrolled

Tumors1 trial

Chemoembolization for Lung Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04200417·10 enrolled

6 more indications

Local1 trial

Localization for Deep Lung Nodules: Microcoil Versus Contrast Injection

Unknown status·NNational Taiwan University Hospital Hsin-Chu Branch·N/A·NCT03617029·60 enrolled

Surgery1 trial

Lipiodol Localization for Ground-glass-opacity Minimal Surgery

Completed·SSeverance Hospital·N/A·NCT02180568·250 enrolled

Biomarkers1 trial

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

Completed·UUniversity of Texas Southwestern Medical Center··NCT04459468·17 enrolled

Gastric Varices1 trial

Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices

Completed·SShanghai Zhongshan Hospital·N/A·NCT01923064·96 enrolled

Endometrial1 trial

Endometrial Effects of Lipiodol

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 3·NCT03542331·20 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT04733092·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for lipiodol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lipiodol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lipiodol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Chia-tai Tianqing Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNanjing Chia-tai Tianqing Pharmaceutical

lipiodol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Hepatocellular Carcinoma8 trials

Liver Cancer2 trials

Colorectal Cancer1 trial

Effectiveness1 trial

Tumors1 trial

Local1 trial

Surgery1 trial

Biomarkers1 trial

Gastric Varices1 trial

Endometrial1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News